Of the researchers of the university of nottingham recently launched a important clinical trial in partnership with many National Health Service (NHS) hospitals and public universities. This project called Vaccine Response On Off Methotrexate (VROOM) was funded by the National Institute for Health and Care Research and the Medical Research Council. It aims to develop new therapies to help the millions of people clinically vulnerable to the pandemic of the Covid-19.
British researchers have notably measured immune responses of those who have been vaccinate once morest Coronavirus. This study then revealed than discontinuing immunosuppressive therapy for a long time allows improve the immune response vulnerable people following a coronavirus vaccine.
Indeed, these people have developed a better immune response once morest COVID-19 than those who have been doubly vaccinated.
Studies conducted on patients taking methotrexate
These research works have been Directed by the Oxford Clinical Trials Research Unit (OCTRU). The researchers were interested in patients who saw themselves prescribe methotrexate for inflammatory diseases and skin conditions such as psoriasis. They understood that this immunosuppressant, although widely used, reduces the body’s ability fight infections and generate a robust response to vaccines.
Or, environ 1.3 million people were prescribed this drug United Kingdom. But the researchers managed to establish relevant results from the data collected from the first 254 participants in the study. The majority of them present morbidity factors which increase their risk of developing severe forms from the malady of COVID-19.
People who stopped immunosuppressants respond better to COVID-19 vaccine
Scientists have examined the impact of discontinuing treatment by methotrexate following a booster vaccination with COVID-19 in adults with autoimmune inflammatory diseases. The decision to discontinue or continue treatment with methotrexate has been made randomly by a computer program.
They then measured the spike antibody levels in the two groups, respectively at four and twelve weeks following their first vaccine dose. Note that the antibody spike prevents the virus from infecting the body’s cells. They then observed a high antibody level in the group that stopped taking the treatment compared to those that continued.
SOURCE : MIRAGNEWS
